Evidence map›Paper›PMID 21084459›Full record

ArticleClinical and vaccine immunology : CVI2011

Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition.

Rebecca Axelsson-Robertson, Raija K Ahmed, Frank F Weichold, Marthie M Ehlers, Marleen M Kock, Donata Sizemore, Jerry Sadoff, Markus Maeurer

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Immunodominant Tuberculosis Antigens Recognized by Human CD4Cold Spring Harbor perspectives in medicine · 2026
    Article
  4. Article
  5. Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022
    Review
  6. Review
  7. Divergent Peptide Presentations of HLA-AFrontiers in immunology · 2019
    Article
  8. Review
  9. Antigens for CD4 and CD8 T cells in tuberculosis.Cold Spring Harbor perspectives in medicine · 2014
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Rebecca Axelsson-RobertsonDepartment of Microbiology and Tumor Cell Biology, Karolinska Institutet, Nobels Väg 18, Stockholm SE-171 82, Sweden.
Raija K Ahmed
Frank F Weichold
Marthie M Ehlers
Marleen M Kock
Donata Sizemore
Jerry Sadoff
Markus Maeurer
Aeras · USUniversity of Pretoria · ZAKarolinska Institutet · SESwedish Institute · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-tuberculosis (TB)-burden countries are located in sub-Saharan Africa. We examined the frequency of human leukocyte antigen (HLA) alleles, followed by recombinant expression of the most frequent HLA-A alleles, i.e., HLA-A*3001 and HLA-A*3002, to study differences in mycobacterial peptide presentation and CD8(+) T-cell recognition. We screened a peptide library (9-mer peptides with an 8-amino-acid overlap) for binding, affinity, and off-rate of the Mycobacterium tuberculosis-associated antigen TB10.4 and identified only three TB10.4 peptides with considerable binding to HLA-A*3001. In contrast, 22 peptides bound to HLA-A*3002. This reflects a marked difference in the binding preference between the two alleles, with A*3002 tolerating a more promiscuous peptide-binding pattern and A*3001 accommodating only a very selective peptide repertoire. Subsequent analysis of the affinity and off-rate of the binding peptides revealed a strong affinity (8 nM to 7 μM) and moderate off-rate (20 min to 3 h) for both alleles. Construction of HLA-A*3001 and HLA-A*3002 tetramers containing selected binding peptides from TB10.4, including a peptide which was shared among both alleles, QIMYNYPAM (TB10.4(3-11)), allowed us to enumerate epitope-specific T cells in HLA-A*3001- and HLA-A*3002-typed patients with active TB. HLA-A*3001 and HLA-A*3002 major histocompatibility complex-peptide complexes were recognized in individuals with active TB, irrespective of their homozygous HLA-A*3001 or HLA-A*3002 genetic background. The antigen-specific T cells exhibited the CD45RA(+) CCR7(+) precursor phenotype and the interleukin-7 receptor (CD127), which were different from the phenotype and receptor exhibited by the parental CD8(+) T-cell population.

Indexed as

Amino Acid SequenceAntigens, BacterialBinding SitesCD8-Positive T-LymphocytesEpitopesHLA-A AntigensHLA AntigensHumansMolecular Sequence DataMycobacterium tuberculosisPeptide LibraryPeptidesProtein BindingSouth AfricaTuberculosis, PulmonaryAntigens, BacterialEpitopesHLA-A*30:01 antigenHLA-A AntigensHLA AntigensPeptide LibraryPeptidesTB10.4 antigen, Mycobacterium tuberculosis

Identifiers

PMID21084459
PMCPMC3019778
OpenAlexW2116821426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.